Target intelligence / Profile preview

Polymerase basic protein 2 subunit of influenza A virus polymerase complex (PB2)

Target
PB2
Molecular classification
Enzyme (RNA-dependent RNA polymerase subunit), Viral protein, Other (cap-binding protein)
01

Overview

The PB2 protein is one of three subunits (alongside PB1 and PA) comprising the influenza A virus RNA polymerase complex. PB2 is responsible for binding the cap structure of host pre-mRNAs, a process called "cap-snatching" that enables the virus to prime transcription of its own mRNAs. PB2 also participates in the assembly and regulation of the polymerase complex, interacts with host factors, and modulates species adaptation and pathogenicity, in part via specific amino acid residues such as Lys627. The structure of PB2, especially the PB1-PB2 interface and cap-binding domain, is highly conserved and is the focus of antiviral drug development. PB2 additionally plays a role in evading host antiviral responses by suppressing interferon signaling pathways. Variations in PB2 are linked to differences in virulence, host range, and susceptibility to drugs.

Other names
PB2Polymerase basic protein 2PB2 subunitInfluenza virus PB2IAV PB2
02

Mechanism of action

Inhibition of cap-binding, blocking "cap-snatching" and viral mRNA synthesis; Disruption of polymerase complex assembly or PB1–PB2 interface; Inhibition of PB2–host protein interactions involved in immune evasion

03

Biological functions

Viral RNA transcriptionViral RNA replicationCap-binding ("cap-snatching" for transcription initiation)Host immune evasion (suppressing interferon signaling)
04

Disease associations

Infection (influenza, pandemic/seasonal flu)Pathogenicity and host range determination
05

Safety considerations

Potential for emergence of viral resistance mutationsFor inhibitors: possible off-target effects, but as PB2 is a viral protein, human side effects are typically related to immunopathology from influenza infection, not direct drug toxicityNeed for broad-spectrum activity to cover diverse PB2 sequences
06

Interacting drugs

VX-787 (pimodivir, a clinical-stage PB2 inhibitor)

1 more in the full profile.

07

Biomarkers

PB2 sequence variants (e.g., residue 627, 283, 526) are associated with increased pathogenicity, host range adaptation, and may guide patient stratification for therapyViral detection using PB2 gene/protein for molecular diagnostics

Beyond the preview

Go deeper on Polymerase basic protein 2 subunit of influenza A virus polymerase complex (PB2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Polymerase basic protein 2 subunit of influenza A virus polymerase complex (PB2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call